01

REMIND Trial: How Remibrutinib 25 mg Twice Daily Was Measured in CIndU

REMIND tested remibrutinib 25 mg twice daily against placebo in three CIndU subtypes, with objective provocation endpoints at 12 weeks and follow-up to 52 weeks.